SANTA ROSA, CA – October 5, 2010 – Osseon Therapeutics, Inc. announced its new Osseoflex® DR Steerable Bone Drill at the North American Spine Society’s (NASS) annual meeting in Orlando, Florida. The physician-controlled drill was designed to facilitate treatment of vertebral compression fractures (VCFs) that may contain sclerotic bone resulting from osteoporosis or fibrotic metastases. The Osseoflex DR Steerable Bone Drill features proprietary technology and allows for unipedicular access to fractures previously considered inaccessible due to dense, sclerotic bone or malignant bone tissue.
“Osseoflex DR is an innovation in VCF therapy. It provides an important tool for cases where VCF needles and balloons are currently inadequate,” said John Stalcup, Ph.D., Osseon’s President and CEO. According to Michael T. Lyster, M.D., Chief Medical Officer, “The Osseoflex DR Steerable Bone Drill further extends our clinical reach beyond purely acute VCFs. We can now access chronic and sub-acute symptomatic bone fractures throughout the axial skeleton.”
Osseon markets the Osseoflex® Steerable Needle and Osseoperm® Bone Cement for the treatment of vertebral compression fractures. Together, they form the Osseoplasty System which represents a safe and effective method for the treatment of VCFs.
Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.
Osseon is a registered trademark of Osseon Therapeutics, Inc.
CONTACT: Michael Bivens, Director of Business Development, Osseon Therapeutics, 707.636.5953